play_arrow
View
64039
AI MED
AI MED — AI Platform for Diagnosis and Therapy Selection
Armenia
Market: Medicine, Artificial Intelligence
Stage of the project: Prototype or product is ready
Date of last change: 29.10.2025
Armenia
Market: Medicine, Artificial Intelligence
Stage of the project: Prototype or product is ready
Date of last change: 29.10.2025
Idea
AI MED — an innovative next-generation medical AI platform that integrates diagnostics, analysis, and personalized recommendations. The system processes MRI, CT, ultrasound, lab tests, and medical history to generate accurate diagnoses, prognoses, and individualized treatment plans. It supports over 30 specialties, including oncology and psychosomatics. AI MED leverages artificial intelligence, machine learning, and biosensors for continuous monitoring, eliminating human error and enhancing diagnostic accuracy.
Current Status
Ready-to-Launch Solution!
A full-featured medical platform with built-in artificial intelligence — fully developed, configured, and ready to deploy.
This is a next-generation, complete model that combines advanced data analysis, diagnostics, and personalized recommendations.
The system requires no further development — simply start using it.
AI MED is ready for implementation and commercial use today.
A full-featured medical platform with built-in artificial intelligence — fully developed, configured, and ready to deploy.
This is a next-generation, complete model that combines advanced data analysis, diagnostics, and personalized recommendations.
The system requires no further development — simply start using it.
AI MED is ready for implementation and commercial use today.
Market
AI MED Clients
AI MED’s clients include medical organizations, physicians, insurance companies, and individual users who are interested in improving diagnostic accuracy, reducing examination time, and integrating artificial intelligence technologies into medical practice.
1. Key Client Segments:
Medical institutions (public and private clinics, diagnostic centers, telemedicine platforms) — interested in automating diagnostics and increasing staff efficiency.
Physicians and specialists — use AI MED as an analytical assistant and decision-support tool.
Patients (ages 25–70) — active digital technology users seeking accessible and accurate solutions for diagnostics, prevention, and health monitoring.
Insurance companies and the corporate sector — aim to reduce healthcare costs and manage employee health risks.
2. Geography:
Primary markets include Europe, the Middle East, and the CIS, where digital healthcare is rapidly developing. Potential clients are also in the USA and Asia, where the HealthTech and medical AI markets are growing at double-digit rates.
3. Market Size and Dynamics:
The global medical AI market was estimated at approximately USD 17 billion in 2024, with projections to reach USD 188 billion by 2030 (CAGR ≈ 38–40%).
The digital diagnostics and medical AI assistant market grows annually by 30% or more.
The potential local market (Europe + CIS) is around USD 2–3 billion over the next five years, with the share of intelligent medical platforms rapidly increasing.
4. Market Future:
The market for intelligent medical platforms as a separate category is just emerging. However, with the growth of telemedicine, wearable devices, and personalized health approaches, demand for such solutions will increase exponentially.
AI MED operates at the intersection of multiple high-growth areas — AI in medicine, telemedicine, digital health, and personalized therapy — making it part of a rapidly expanding multi-billion-dollar segment.
AI MED’s clients include medical organizations, physicians, insurance companies, and individual users who are interested in improving diagnostic accuracy, reducing examination time, and integrating artificial intelligence technologies into medical practice.
1. Key Client Segments:
Medical institutions (public and private clinics, diagnostic centers, telemedicine platforms) — interested in automating diagnostics and increasing staff efficiency.
Physicians and specialists — use AI MED as an analytical assistant and decision-support tool.
Patients (ages 25–70) — active digital technology users seeking accessible and accurate solutions for diagnostics, prevention, and health monitoring.
Insurance companies and the corporate sector — aim to reduce healthcare costs and manage employee health risks.
2. Geography:
Primary markets include Europe, the Middle East, and the CIS, where digital healthcare is rapidly developing. Potential clients are also in the USA and Asia, where the HealthTech and medical AI markets are growing at double-digit rates.
3. Market Size and Dynamics:
The global medical AI market was estimated at approximately USD 17 billion in 2024, with projections to reach USD 188 billion by 2030 (CAGR ≈ 38–40%).
The digital diagnostics and medical AI assistant market grows annually by 30% or more.
The potential local market (Europe + CIS) is around USD 2–3 billion over the next five years, with the share of intelligent medical platforms rapidly increasing.
4. Market Future:
The market for intelligent medical platforms as a separate category is just emerging. However, with the growth of telemedicine, wearable devices, and personalized health approaches, demand for such solutions will increase exponentially.
AI MED operates at the intersection of multiple high-growth areas — AI in medicine, telemedicine, digital health, and personalized therapy — making it part of a rapidly expanding multi-billion-dollar segment.
Problem or Opportunity
Client Description and the Problem AI MED Solves
Our clients include both medical institutions and individual users who face slow and inaccurate diagnostics, high medical costs, and the impact of human factors on treatment quality.
Modern healthcare is overloaded; doctors are pressed for time, and patients often receive incomplete or conflicting diagnoses. Up to 30% of diagnostic errors result from cognitive biases, fatigue, and the limitations of human analysis.
Our clients include both medical institutions and individual users who face slow and inaccurate diagnostics, high medical costs, and the impact of human factors on treatment quality.
Modern healthcare is overloaded; doctors are pressed for time, and patients often receive incomplete or conflicting diagnoses. Up to 30% of diagnostic errors result from cognitive biases, fatigue, and the limitations of human analysis.
Solution (product or service)
AI MED is the world’s first full-featured next-generation medical AI platform capable of comprehensively analyzing imaging (MRI, CT, ultrasound), lab tests, medical history, and patient complaints to generate an accurate diagnosis, prognosis, and personalized treatment plan.
The system combines the roles of a physician-diagnostician, analyst, and consultant, providing a level of analysis unattainable by humans, even taking into account the patient’s psycho-emotional state.
Why clients will pay:
Medical institutions gain a tool that increases diagnostic accuracy and speed, reduces staff workload, and minimizes the risk of errors.
Private clinics can leverage AI MED to attract patients by offering an innovative “one-click” diagnostic solution.
Patients gain access to an intelligent system that helps identify the root causes of illness, select therapy, and monitor their condition in real time.
AI MED’s advantage lies in its uniqueness — no other system on the market combines image processing, data analysis, medical reasoning, NLP, and psycho-emotional assessment in a single solution.
This makes AI MED a revolutionary platform that sets a new standard for 21st-century medical diagnostics. Clinics and patients are willing to pay for it because it saves time, reduces risks, and improves treatment effectiveness.
The system combines the roles of a physician-diagnostician, analyst, and consultant, providing a level of analysis unattainable by humans, even taking into account the patient’s psycho-emotional state.
Why clients will pay:
Medical institutions gain a tool that increases diagnostic accuracy and speed, reduces staff workload, and minimizes the risk of errors.
Private clinics can leverage AI MED to attract patients by offering an innovative “one-click” diagnostic solution.
Patients gain access to an intelligent system that helps identify the root causes of illness, select therapy, and monitor their condition in real time.
AI MED’s advantage lies in its uniqueness — no other system on the market combines image processing, data analysis, medical reasoning, NLP, and psycho-emotional assessment in a single solution.
This makes AI MED a revolutionary platform that sets a new standard for 21st-century medical diagnostics. Clinics and patients are willing to pay for it because it saves time, reduces risks, and improves treatment effectiveness.
Competitors
Competitors and Alternatives
At the current stage, AI MED has no direct competitors offering a comprehensive solution that integrates all key medical AI technologies on a single platform — from medical imaging and lab data analysis to generating diagnoses, prognoses, therapeutic recommendations, and accounting for the patient’s psycho-emotional state.
Existing market solutions (IBM Watson Health, Google DeepMind Health, Babylon Health, etc.) provide only partial analogs, focusing on specific tasks such as image analysis, chatbot consultations, or physician decision support. They do not offer a holistic approach, integration with biosensors, or continuous patient monitoring.
Thus, AI MED is creating a new category in the medical AI market — an intelligent multi-component platform, a “next-generation physician-analyst.”
This provides a unique competitive advantage and the opportunity to secure a leading position in the emerging segment, without competing directly with existing specialized services.
At the current stage, AI MED has no direct competitors offering a comprehensive solution that integrates all key medical AI technologies on a single platform — from medical imaging and lab data analysis to generating diagnoses, prognoses, therapeutic recommendations, and accounting for the patient’s psycho-emotional state.
Existing market solutions (IBM Watson Health, Google DeepMind Health, Babylon Health, etc.) provide only partial analogs, focusing on specific tasks such as image analysis, chatbot consultations, or physician decision support. They do not offer a holistic approach, integration with biosensors, or continuous patient monitoring.
Thus, AI MED is creating a new category in the medical AI market — an intelligent multi-component platform, a “next-generation physician-analyst.”
This provides a unique competitive advantage and the opportunity to secure a leading position in the emerging segment, without competing directly with existing specialized services.
Advantages or differentiators
Undeniable Advantages and Differentiators of AI MED
AI MED possesses a range of unique advantages that cannot be directly replicated in the short term due to its combination of technologies, system architecture, and intelligent learning model.
1. Comprehensive Approach (Unique Architecture):
AI MED integrates medical imaging analysis (MRI, CT, ultrasound), lab data, medical history, patient complaints, and psycho-emotional factors into a single platform.
No other system in the world currently offers this level of integration.
2. Medical Reasoning System (Intelligent Decision Logic):
Unlike existing AI services, AI MED does more than recognize data — it establishes cause-and-effect relationships between symptoms, tests, and patient condition, generating a complete medical report, diagnosis, and prognosis.
3. Personalization and Adaptive Learning:
The system uses reinforcement learning and self-training based on feedback from doctors and users. This makes each deployment unique and complicates replication of its operational mechanics.
4. Integration with Biosensors and Real-Time Monitoring:
AI MED can analyze data from fitness trackers, cardiac monitors, glucometers, and other devices, providing continuous medical supervision, which most competitors lack.
5. Psychosomatic Module:
The system accounts for the patient’s emotional and mental state, elevating diagnostics and therapy to a new level of complexity and personalization.
6. Zero Bias and High Objectivity:
AI MED is not affected by human cognitive or emotional biases, significantly reducing the risk of diagnostic errors.
In summary, AI MED cannot be reproduced through simple technology copying — its strength lies in the unique combination of artificial intelligence, medical reasoning, and data integration, creating a new generation of digital medicine.
AI MED possesses a range of unique advantages that cannot be directly replicated in the short term due to its combination of technologies, system architecture, and intelligent learning model.
1. Comprehensive Approach (Unique Architecture):
AI MED integrates medical imaging analysis (MRI, CT, ultrasound), lab data, medical history, patient complaints, and psycho-emotional factors into a single platform.
No other system in the world currently offers this level of integration.
2. Medical Reasoning System (Intelligent Decision Logic):
Unlike existing AI services, AI MED does more than recognize data — it establishes cause-and-effect relationships between symptoms, tests, and patient condition, generating a complete medical report, diagnosis, and prognosis.
3. Personalization and Adaptive Learning:
The system uses reinforcement learning and self-training based on feedback from doctors and users. This makes each deployment unique and complicates replication of its operational mechanics.
4. Integration with Biosensors and Real-Time Monitoring:
AI MED can analyze data from fitness trackers, cardiac monitors, glucometers, and other devices, providing continuous medical supervision, which most competitors lack.
5. Psychosomatic Module:
The system accounts for the patient’s emotional and mental state, elevating diagnostics and therapy to a new level of complexity and personalization.
6. Zero Bias and High Objectivity:
AI MED is not affected by human cognitive or emotional biases, significantly reducing the risk of diagnostic errors.
In summary, AI MED cannot be reproduced through simple technology copying — its strength lies in the unique combination of artificial intelligence, medical reasoning, and data integration, creating a new generation of digital medicine.
Finance
AI MED Financial Model and Sales Forecast
AI MED is a scalable medical AI platform designed for both B2B and B2C monetization models.
Main Revenue Sources:
Licensing and subscriptions for clinics and diagnostic centers — USD 3,000 to 10,000 per year, depending on feature set and number of users.
Personal subscriptions for individual users — USD 15 to 50 per month.
Integrations and white-label solutions for telemedicine services and insurance companies — starting at USD 50,000 per implementation.
Additional services: biosensor integration, Big Data analysis, and customization to client needs.
Sales Forecast (with phased scaling):
Year 1: Pilot integrations, revenue ~$300,000
Year 2: Expansion to international markets, ~$1.5 million
Year 3: Expanded functionality and coverage of 50+ clinics, ~$5 million
Year 4: Mass commercialization, EMR and wearable integrations, ~$12 million
Year 5: Stable client flow and B2C segment, $20+ million annually
Profitability: Expected at 35–45% due to low scaling costs and high-margin digital services.
Market Potential: Over the next five years, AI MED could capture 0.01–0.05% of the global medical AI market. With the projected market size exceeding USD 180 billion, this makes AI MED a highly profitable and investment-attractive project.
AI MED is a scalable medical AI platform designed for both B2B and B2C monetization models.
Main Revenue Sources:
Licensing and subscriptions for clinics and diagnostic centers — USD 3,000 to 10,000 per year, depending on feature set and number of users.
Personal subscriptions for individual users — USD 15 to 50 per month.
Integrations and white-label solutions for telemedicine services and insurance companies — starting at USD 50,000 per implementation.
Additional services: biosensor integration, Big Data analysis, and customization to client needs.
Sales Forecast (with phased scaling):
Year 1: Pilot integrations, revenue ~$300,000
Year 2: Expansion to international markets, ~$1.5 million
Year 3: Expanded functionality and coverage of 50+ clinics, ~$5 million
Year 4: Mass commercialization, EMR and wearable integrations, ~$12 million
Year 5: Stable client flow and B2C segment, $20+ million annually
Profitability: Expected at 35–45% due to low scaling costs and high-margin digital services.
Market Potential: Over the next five years, AI MED could capture 0.01–0.05% of the global medical AI market. With the projected market size exceeding USD 180 billion, this makes AI MED a highly profitable and investment-attractive project.
Business model
AI MED Business Model, Sales Channels, and Key Metrics
1. Business Model:
AI MED operates on a hybrid monetization model (B2B + B2C):
B2B — licensing and subscriptions for clinics, diagnostic centers, telemedicine platforms, and insurance companies.
Annual subscription: USD 3,000–10,000 depending on the number of users and modules.
White-label integrations and API access: from USD 50,000.
B2C — personal subscription for individual users: USD 15–50 per month.
Additional revenue streams: medical data analysis (Big Data), model training based on clinic data, paid consulting modules, and wearable device integration.
2. Sales Channels:
Direct sales to medical organizations and corporate clients through a sales team and partner network.
Online marketing and promotion via medical and technology conferences, specialized media, and professional communities.
Partnerships with telemedicine services, insurance companies, and biosensor manufacturers.
Digital health platforms and apps (App Store, Google Play, and proprietary web interface).
3. Key Performance Metrics:
Active users (MAU, DAU): target growth to 1 million users within 5 years.
Number of connected clinics and partners: >500 over 5 years.
CAC (Customer Acquisition Cost) and LTV (Lifetime Value): key indicators of profitability.
Diagnostic recommendation accuracy: target ≥95%.
Retention rate: >75% through personalization and high trust.
EBITDA: expected positive from year 3 of scaling.
AI MED creates long-term value by integrating into medical ecosystems, improving efficiency for clinics while providing users with access to a highly accurate digital “physician.”
1. Business Model:
AI MED operates on a hybrid monetization model (B2B + B2C):
B2B — licensing and subscriptions for clinics, diagnostic centers, telemedicine platforms, and insurance companies.
Annual subscription: USD 3,000–10,000 depending on the number of users and modules.
White-label integrations and API access: from USD 50,000.
B2C — personal subscription for individual users: USD 15–50 per month.
Additional revenue streams: medical data analysis (Big Data), model training based on clinic data, paid consulting modules, and wearable device integration.
2. Sales Channels:
Direct sales to medical organizations and corporate clients through a sales team and partner network.
Online marketing and promotion via medical and technology conferences, specialized media, and professional communities.
Partnerships with telemedicine services, insurance companies, and biosensor manufacturers.
Digital health platforms and apps (App Store, Google Play, and proprietary web interface).
3. Key Performance Metrics:
Active users (MAU, DAU): target growth to 1 million users within 5 years.
Number of connected clinics and partners: >500 over 5 years.
CAC (Customer Acquisition Cost) and LTV (Lifetime Value): key indicators of profitability.
Diagnostic recommendation accuracy: target ≥95%.
Retention rate: >75% through personalization and high trust.
EBITDA: expected positive from year 3 of scaling.
AI MED creates long-term value by integrating into medical ecosystems, improving efficiency for clinics while providing users with access to a highly accurate digital “physician.”
Money will be spent on
Full-scale global launch of the project
Offer for investor
The investor will receive a portion of the shares in our project, with the exact amount to be negotiated directly with the investor and formalized notarially.
Team or Management
Risks
At the present time, the main risks are the lack of advertising and the absence of full partner funding necessary for the complete launch of the project.
Photos
Product Video
Presentation
Sign in/Sign up